Literature DB >> 7777163

c-fos antisense oligodeoxynucleotide increases formalin-induced nociception and regulates preprodynorphin expression.

J C Hunter1, V L Woodburn, C Durieux, E K Pettersson, J A Poat, J Hughes.   

Abstract

Rats, receiving an intrathecal pretreatment of oligodeoxynucleotide complementary to c-fos mRNA (antisense), showed no increases in Fos protein or preprodynorphin messenger RNA in the outer laminae of the lumbar spinal cord when challenged 4 h later with a 50 microliters intraplantar injection of 5% formalin. Animals pretreated with saline or sense oligodeoxynucleotide showed marked increases in Fos protein (2 h after formalin challenge) and preprodynorphin mRNA (20 h after formalin challenge) in the lumbar region of the cord ipsilateral to the side of the injection. The behavioural consequences of antisense pretreatment were an increase in the formalin-induced licking/biting responses during the tonic, but not the acute phase. These observations could be interpreted as representing a sequence of events beginning with the formalin-induced increase in the transcription factor Fos, which in turn increases the synthesis of preprodynorphin messenger RNA resulting in the production of the dynorphin opioid peptides which then exert a modulatory antinociceptive action.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7777163     DOI: 10.1016/0306-4522(94)00500-5

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  11 in total

1.  Expansion of formalin-evoked Fos-immunoreactivity in rats with a spinal cord injury.

Authors:  Daniel A Castellanos; Linda A Daniels; Mena P Morales; Aldric T Hama; Jacqueline Sagen
Journal:  Neurosci Res       Date:  2007-05-03       Impact factor: 3.304

2.  Protein kinase A-dependent derepression of the human prodynorphin gene via differential binding to an intragenic silencer element.

Authors:  A M Carrión; B Mellström; J R Naranjo
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

3.  Phosphorylation of transcription factor CREB in rat spinal cord after formalin-induced hyperalgesia: relationship to c-fos induction.

Authors:  R R Ji; F Rupp
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

4.  An antisense oligonucleotide reverses the footshock-induced expression of fos in the rat medial prefrontal cortex and the subsequent expression of conditioned fear-induced immobility.

Authors:  B A Morrow; J D Elsworth; F M Inglis; R H Roth
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

5.  Can Pulsed Radiofrequency of the Occipital Nerves Cause Sedation? A New Perspective of Existing Knowledge.

Authors:  Chrysa Arvaniti; Alia Ibrahim Madi; Georgia Kostopanagiotou; Chrysanthi Batistaki
Journal:  Anesth Pain Med       Date:  2020-04-13

6.  Prolonged nociceptive responses to hind paw formalin injection in rats with a spinal cord injury.

Authors:  Jeung Woon Lee; Orion Furmanski; Daniel A Castellanos; Linda A Daniels; Aldric T Hama; Jacqueline Sagen
Journal:  Neurosci Lett       Date:  2008-05-15       Impact factor: 3.046

7.  c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxious stimulation and tissue injury?

Authors:  Yong-Jing Gao; Ru-Rong Ji
Journal:  Open Pain J       Date:  2009-01-01

8.  Treatment experience of pulsed radiofrequency under ultrasound guided to the trapezius muscle at myofascial pain syndrome -a case report-.

Authors:  Chung Hoon Park; Yoon Woo Lee; Yong Chan Kim; Joo Hwa Moon; Jong Bum Choi
Journal:  Korean J Pain       Date:  2012-01-02

9.  Pulsed Radiofrequency (PRF) of Pericapsular Nerves Group (PENG) in Chronic Hip Pain-A Case Report.

Authors:  Ashok Jadon
Journal:  Turk J Anaesthesiol Reanim       Date:  2021-12

10.  Pulsed radiofrequency treatment of articular branches of femoral and obturator nerves for chronic hip pain.

Authors:  Cien-Leong Chye; Cheng-Loong Liang; Kang Lu; Ya-Wen Chen; Po-Chou Liliang
Journal:  Clin Interv Aging       Date:  2015-03-16       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.